A5087980707- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Cardiac Arrest and Resuscitation
- Transplantation: Methods and Outcomes
- Cardiac pacing and defibrillation studies
- Cardiac Valve Diseases and Treatments
- Congenital Heart Disease Studies
- Fuel Cells and Related Materials
- Renal Transplantation Outcomes and Treatments
- Cardiac and Coronary Surgery Techniques
- Organ Transplantation Techniques and Outcomes
- Viral Infections and Immunology Research
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Ischemia and Reperfusion
- Infective Endocarditis Diagnosis and Management
- Tissue Engineering and Regenerative Medicine
- Cardiac Arrhythmias and Treatments
- Pain Management and Treatment
- Aortic Disease and Treatment Approaches
- Cardiac Imaging and Diagnostics
- Organ and Tissue Transplantation Research
- Cardiac tumors and thrombi
- Cardiac, Anesthesia and Surgical Outcomes
- Atrial Fibrillation Management and Outcomes
Baylor College of Medicine
2015-2024
St. Luke's Hospital
2015-2023
Texas Cardiac Arrhythmia
2013-2021
The University of Texas Health Science Center at Houston
1978-2017
Texas Diabetes Institute
2015-2017
University of Louisville
2016
BiVACOR (United States)
2016
St. Luke's Episcopal Hospital
2006-2015
Zagazig University
2014
Virginia Department of Environmental Quality
2014
Implantable left ventricular assist devices have benefited patients with end-stage heart failure as a bridge to cardiac transplantation, but their long-term use for the purpose of enhancing survival and quality life has not been evaluated.
Patients with advanced heart failure have improved survival rates and quality of life when treated implanted pulsatile-flow left ventricular assist devices as compared medical therapy. New continuous-flow are smaller may be more durable than the devices.In this randomized trial, we enrolled patients who were ineligible for transplantation, in a 2:1 ratio, to undergo implantation device (134 patients) or currently approved (66 patients). The primary composite end point was, at 2 years, free...
The use of left ventricular assist devices is an accepted therapy for patients with refractory heart failure, but current pulsatile volume-displacement have limitations (including large pump size and limited long-term mechanical durability) that reduced widespread adoption this technology. Continuous-flow pumps are newer types developed to overcome some these limitations.In a prospective, multicenter study without concurrent control group, 133 end-stage failure who were on waiting list...
In animal models of lipotoxicity, accumulation triglycerides within cardiomyocytes is associated with contractile dysfunction. However, whether intramyocardial lipid deposition a feature human heart failure remains to be established. We hypothesized that common non-ischemic and changes in gene expression similar those found an model lipotoxicity. Intramyocardial staining oil red O analysis was performed on tissue from 27 patients (9 female) failure. determined lipid, expression, function...
Background — Previous studies suggest that the failing heart reactivates fetal genes and reverts to a pattern of energy substrate metabolism. We tested this hypothesis by examining metabolic gene expression profiles in fetal, nonfailing, human heart. Methods Results Human left ventricular tissue (apex) was obtained from 9 10 adult hearts. Using quantitative reverse transcription-polymerase chain reaction, we measured transcript levels atrial natriuretic factor, myosin heavy chain-α -β, 13...
Background— Myocardial recovery after left ventricular assist device (LVAD) support has been reported. The LVAD Working Group Recovery Study was a prospective multicenter trial to assess the incidence of myocardial in patients bridged cardiac transplantation. Methods and Results— After implantation, were evaluated with use rest echocardiograms partial cardiopulmonary exercise testing. Dobutamine echocardiography hemodynamic measurements performed those ejection fraction >40% during...
Objective This nonrandomized study using concurrent controls was performed to determine whether the HeartMate implantable pneumatic (IP) left ventricular assist system (LVAS) could provide sufficient hemodynamic support allow rehabilitation of severely debilitated transplant candidates and evaluate such reduced mortality before after transplantation. Methods Outcomes 75 LVAS patients were compared with outcomes 33 control (not treated an LVAS) at 17 centers in United States. All who met...
Background —An increasing number of observations in patients with end-stage heart failure suggest that chronic ventricular unloading by mechanical circulatory support may lead to recovery cardiac function. Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine capable producing pulmonary edema, dilated cardiomyopathy, and death. TNF-α produced the myocardium response volume overload; however, effects normalizing loading conditions on myocardial expression are not known. We hypothesize...
The SEP identified priorities to support in future basic and clinical research pointed out directions likely result advances against heart failure. list is not intended be all-encompassing does address, for example, exciting lines of work already under way. Rather, the recommendations are designed point gaps current knowledge being adequately addressed highly promising new directions. Although incidence failure continues grow, emerging provide hope that will eventually lead more effective...